Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score on Rankin scale · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean disability score at 24 weeks or later · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with CIDP
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with prednisolone (moderate certainty).
1 finding from 1 review
Event‐free survival (no death, transplant, or left ventricular assist device) ‐ adults with myocarditis · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes event‐free survival (risk of death, cardiac transplant, or left… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival (risk of death) ‐ adults with myocarditis, median · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ adults with myocarditis, median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Side effects ‐ mild infusion effects, 12‐month · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes side effects ‐ mild infusion effects, 12‐month compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival (risk of death) ‐ children with myocarditis, 6‐month · children with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ children with myocarditis, 6‐month compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Postoperative opioid consumption, 'overall' (MEQ, mg) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Gastrointestinal recovery · adults undergoing surgery with general anaesthesia
It is very uncertain whether intravenous (IV) lidocaine changes gastrointestinal recovery compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse events (e.g. the number of participants that died, or had arrhythmias, other heart rate disorders, or showed any signs of lidocaine toxicity) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Nausea · adults undergoing surgery with general anaesthesia
It is very uncertain whether intravenous (IV) lidocaine changes postoperative nausea, 'overall' (0 to 24 h, to 48 h, to 72 h) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Postoperative opioid consumption, 'overall' (MEQ, mg) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Gastrointestinal recovery · adults undergoing surgery with general anaesthesia
1 finding from 1 review